We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

50 hedge funds and large institutions have $213M invested in Albireo Pharma Inc in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

161% more capital invested

Capital invested by funds: $81.8M → $213M (+$131M)

150% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 6

67% more funds holding

Funds holding: 30 → 50 (+20)

Holders
50
Holders Change
+20
Holders Change %
+66.67%
% of All Funds
1.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
15
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$21.1M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$13.6M
3
PA
Perceptive Advisors
New York
+$12.9M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$10.4M
5
AG
Artal Group
Luxembourg
+$8.35M

Top Sellers

Rank Fund Capital Flow
1
SAM
Sectoral Asset Management
Quebec, Canada
-$2.36M
2
Renaissance Technologies
Renaissance Technologies
New York
-$953K
3
SFM
Sphera Funds Management
Israel
-$907K
4
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
-$51K
5
Morgan Stanley
Morgan Stanley
New York
-$29.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
BlueCrest Capital Management
Jersey
$709K +$733K +21,775 New
TEE
27
Tibra Equities Europe
United Kingdom
$590K +$609K +18,101 New
EP
28
Eversept Partners
New York
$587K +$607K +18,029 New
AAP
29
Ardsley Advisory Partners
Connecticut
$535K +$162K +4,800 +42%
PPA
30
Parametric Portfolio Associates
Washington
$533K +$551K +16,355 New
Northern Trust
31
Northern Trust
Illinois
$513K +$200K +5,932 +60%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$345K +$72.1K +2,140 +25%
ECM
33
Element Capital Management
New York
$335K +$346K +10,283 New
JMH
34
J.M. Hartwell
New York
$329K +$23.6K +700 +7%
UBS Group
35
UBS Group
Switzerland
$298K – – –
Morgan Stanley
36
Morgan Stanley
New York
$282K -$29.2K -866 -9%
CS
37
Credit Suisse
Switzerland
$226K +$234K +6,939 New
LCM
38
Laurion Capital Management
New York
$210K +$217K +6,438 New
Wells Fargo
39
Wells Fargo
California
$200K -$7.64K -227 -4%
Barclays
40
Barclays
United Kingdom
$192K -$27.2K -807 -12%
Bank of Montreal
41
Bank of Montreal
Ontario, Canada
$142K +$146K +4,330 New
PCM
42
Prelude Capital Management
New York
$83K +$19K +563 +28%
TDC
43
Thompson Davis & Co
Virginia
$49K +$43.5K +1,292 +587%
Bank of America
44
Bank of America
North Carolina
$48K +$49.8K +1,479 +36,975%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$11K -$34 -1 -0.3%
VIA
46
Vantage Investment Advisors
Pennsylvania
$7K +$6.73K +200 New
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$3K +$3.03K +90 +900%
Deutsche Bank
48
Deutsche Bank
Germany
$3K +$3.37K +100 New
PMFA
49
Plante Moran Financial Advisors
Michigan
$2K – – –
SFM
50
Sphera Funds Management
Israel
– -$907K -35,431 Closed
1
2
3

ALBO Hedge Fund Activity: Q1 2018 in Review

50 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2018, worth a combined $213M — up 161% from $81.8M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ALBO positions and 5 closed out — a net gain of 20 holders — while 15 added to existing stakes and 6 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $21.1M. The largest seller was Sectoral Asset Management, cutting an estimated $2.36M.

  • 50 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2018, up from 30 in Q4 2017.
  • Funds reported $213M of Albireo Pharma Inc stock for Q1 2018, up 161% quarter-over-quarter.
  • 25 funds opened new Albireo Pharma Inc positions in Q1 2018 and 5 closed out, a net change of +20 holders.
  • The largest Albireo Pharma Inc buyer in Q1 2018 was Fidelity Investments, an estimated $21.1M added.
  • The largest Albireo Pharma Inc seller in Q1 2018 was Sectoral Asset Management, an estimated $2.36M sold.

Based on aggregated 13F filings for Q1 2018.